Global Ovarian Cancer Therapeutics in APAC Market is expected to grow at a CAGR of 5.1% to 2020


Posted March 7, 2016 by MIR114

OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.

 
MarketIntelReports Research, a leading business intelligence provider, has released its latest research report, "Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches". The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).

Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.

Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidate’s olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.

[b]Check Complete Report @[/b] http://www.marketintelreports.com/report/gbihc351mr/ovarian-cancer-therapeutics-in-asia-pacific-markets-to-2020--off-patent-chemo-regimens-to-retain-dominance-despite-new-launches

[b]Scope of the Report:[/b]
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes -
• A brief introduction to OC, including the disease’s pathogenesis, risk factors and diagnosis
• In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
• A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
• Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
• Discussion of the drivers and barriers for market growth
• In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals

[b]Get Sample Brochure of the Report @[/b] http://www.marketintelreports.com/pdfdownload.php?id=gbihc351mr

[b]Reasons to Buy:[/b]
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
• Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
• Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
• Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
• Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
• Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market

[b]Order a copy of Ovarian Cancer Therapeutics in APAC Market Report @[/b] http://www.marketintelreports.com/purchase.php?id=gbihc351mr

[b]About us:[/b]
[b]MarketIntelReports (MIR)[/b] aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
[b]MarketIntelReports[/b] currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

[b]Contact us:[/b]
[b]Mayur S[/b]
Sales Manager
2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808
United States
www.marketintelreports.com
[email protected]
Telephone: 1-302-684-6088
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By MarketIntelReports
Country United States
Categories Health
Tags ovarian cancer therapeutics in apac market , ovarian cancer therapeutics in apac market analysis , ovarian cancer therapeutics in apac market forecast , ovarian cancer therapeutics in apac market growth , ovarian cancer therapeutics in apac market size , ovarian cancer therapeutics in apac market trends
Last Updated March 7, 2016